Properties and applications of antimicrobial peptides in biodefense against biological warfare threat agents

Critical Reviews in Microbiology

Volumn 34, Issue 2, 2008, Pages 89-107

  Dawson, Raymond Murray ^a   Liu, Chun Qiang ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Anthrax; Antimicrobial Peptide; Biological Warfare; Multivalency

Indexed keywords

ANTIBIOTIC AGENT; ARGINYLTRYPTOPHYLCYSTEINYLVALYLTYROSYLALANYLTYROSYLVALYL ARGINYLVALYLARGINYLGLYCYLVALYLLEUCYLVALYLARGINYLTYROSYLARGINYLARGINYL CYSTEINYLTRYPTOPHANAMIDE; ARGINYLTRYPTOPHYLSERYLVALYLTYROSYLALANYLTYROSYLVALYLARGINYLVALY LARGINYLGLYCYLVALYLLEUCYLVALYLARGINYLTYROSYLARGINYLARGINYLSERYLTRYPTOPHANAMIDE; ARGINYLVALYLLYSYLARGINYLVALYLTRYPTOPHYLPROLYLLEUCYLVALYLISOL EUCYLARGINYLTHREONYLVALYLISOLEUCYLALANYLGLYCYLTYROSYLASPARAGINYLLEUCYL TYROSYLARGINYLALANYLISOLEUCYLLYSYLLYSYLLYSINAMIDE; CATHELICIDIN; DEFENSIN; DERMASEPTIN; DERMCIDIN; GLYCYLLYSYLPROLYLARGINYLPROLYLTYROSYLSERYLPROLYLARGINYLPROLYL THREONYLSERYLHISTIDYLPROLYLARGINYLPROLYLISOLEUCYLARGINYLVALINAMIDE; GLYCYLLYSYLPROLYLARGINYLPROLYLTYROSYLTHREONYLPROLYLARGINYLPROLYL THREONYLSERYLHISTIDYLPROLYLARGINYLPROLYLISOLEUCYLARGINYLVALINAMIDE; GLYCYLPHENYLALANYLSERYLSERYLLEUCYLPHENYLALANYLLYSYLALANYLGLYCYLALANYL LYSYLTYROSYLLEUCYLLEUCYLLYSYLSERYLVALYLGLYCYLLYSYLALANYLGLYCYLALANYL GLUTAMINYLGLUTAMINYLLEUCYLALANYLCYSTEINYLLYSYLALANYLALANYLASPARAGINYL ASPARAGINYLCYSTEINYLALANINAMIDE; GLYCYLVALYLISOLEUCYLTHREONYLASPARTYLALANYLLEUCYLLYSYLGLYCYLALANYLALANYL LYSYLTHREONYLVALYLALANYLALANYLGLUTAMYLLEUCYLLEUCYLARGINYLLYSYLALANYL HISTIDYLCYSTEINYLLYSYLLEUCYLTHREONYLASPARAGINYLSERYLCYSTEINAMIDE; HEPCIDIN; HISTATIN; LACTOFERRIN; LANTIOBIOTIC; LEUCYLASPARAGINYLLEUCYLLYSYLGLYCYLISOLEUCYLPHENYLALANYL LYSYLLYSYLVALYLALANYLSERYLLEUCYLLEUCYLTHREONINAMIDE; LIPOPEPTIDE; LYSYLASPARAGINYLLEUCYLARGINYLISOLEUCYLISOLEUCYLARGINYLLYSYLGLYCYL ISOLEUCYLHISTIDYLISOLEUCYLISOLEUCYLLYSYLLYSYLTYROSINAMIDE; MAGAININ DERIVATIVE; PHENYLALANYLLEUCYLGLYCYLVALYLVALYLPHENYLALANYLLYSYLLEUCYLALANYLSERYL LYSYLVALYLPHENYLALANYLPROLYLALANYLVALYLPHENYLALANYLGLYCYLLYSYLVALINAMIDE; PHENYLALANYLLEUCYLPHENYLALANYLARGINYLVALYLALANYLSERYLLYSYLVALYL PHENYLALANYLPROLYLALANYLLEUCYLISOLEUCYLGLYCYLLYSYLPHENYLALANYLLYSYLLYSYL LYSINAMIDE; PHENYLALANYLLYSYLARGINYLLEUCYLGLUTAMYLLYSYLLEUCYLPHENYLALANYLSERYL LYSYLISOLEUCYLTRYPTOPHYLASPARAGINYLTRYPTOPHYLLYSINAMIDE; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; SERYLGLYCYLSERYLLEUCYLSERYLTHREONYLPHENYLALANYLPHENYLALANYLARGINYL LEUCYLPHENYLALANYLASPARAGINYLARGINYLSERYLPHENYLALANYLTHREONYLGLUTAMINYLALANYL LEUCYLGLYCYLLYSINAMIDE; SERYLISOLEUCYLTRYPTOPHYLGLUTAMYLGLYCYLISOLEUCYLLYSYLASPARAGINYLALANYL GLYCYLLYSYLGLYCYLPHENYLALANYLLEUCYLVALYLSERYLISOLEUCYLLEUCYLASPARTYL LYSYLVALYLARGINYLCYSTEINYLLYSYLVALYLALANYLGLYCYLGLYCYLCYSTEINYLASPARAGINYL PROLINAMIDE; STREPTOMYCIN; THREONYLPHENYLALANYLPHENYLALANYLARGINYLLEUCYLPHENYLALANYL ASPARAGINYLARGINYLSERYLPHENYLALANYLTHREONYLGLUTAMINYLALANYLLEUCYLGLYCYL LYSINAMIDE; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACILLUS ANTHRACIS; BACTERIAL MEMBRANE; BIOLOGICAL WARFARE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HEMOLYSIS; HOST CELL; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; BASE SEQUENCE; BIOLOGICAL WARFARE AGENTS; COMMUNICABLE DISEASES; DRUG RESISTANCE, MICROBIAL; DRUG STABILITY; HUMANS; MOLECULAR CONFORMATION; PEPTIDES;

BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 45849124660     PISSN: 1040841X     EISSN: 15497828     Source Type: Journal    
DOI: 10.1080/10408410802143808     Document Type: Review

References (97)

1. Agerberth, B., and Gudmundsson, G.H. 2006. Host antimicrobial defense peptides in human disease. Curr. Topics Microbiol. Immunol. 306, 67-90.
2. Andra, J., Monreal, D., Martinez de Tejada, G., Olak., C., Brezesinski, G., Sanchez Gomez, S., Goldmann, T., Bartels, R., Brandenburg, K., and Moriyon, I. 2007. Rationale for the design of shortened derivatives of the NK-lysin derived antimicrobial peptide NK-2 with improved activity against Gram-negative pathogens. J. Biol. Chem. 282, 14719-14728.
3. Arcisio-Miranda, M., Perez dos Santos Cabrera, M., Konno, K., Rangel, M.,and Procopio, J. 2008. Effects of the cationic antimicrobial peptide eumenitin from the venom of solitary wasp Eumenes rubronotatus in planar lipid bilayers: Surface charge and pore formation activity. Toxicon 51, 736-745.
4. Baillie, L.W., Fowler, K., and Turnbull, P.C. 1999. Human immune responses to the U.K. human anthrax vaccine. J. Appl. Microbiol. 87, 306-308.
5. Bals, R., and Hiemstra, P.S. 2006. Antimicrobial peptides in COPD - basic biology and therapeutic applications. Curr. Drug Targets 7, 743-750.
6. Bals, R., and Wilson, J.M. 2003. Cathelicidins - a family of multifunctional antimicrobial peptides. Cell. Mol. Life Sci. 60, 711-720.
7. Barak, O., Treat, J.R., and James, W.D. 2005. Antimicrobial Peptides: Effectors of innate immunity in the skin. Adv. Dermatol. 21, 357-374.
8. Batoni, G., Maisetta, G., Esin, S., and Campa, M. 2006. Human beta-defensin-3: A promising antimicrobial peptide. Mini Rev. Med. Chem. 6, 1063-1073.
9. Bhalla, D.K., and Warheit, D.B. 2004. Biological agents with potential for misuse: A historical perspective and defensive measures. Toxicol. Appl. Pharmacol. 199, 71-84.
10. Bikker, F.J., Kaman-van Zantan, W.E., de Vries-van de Ruit, A.-M. B.C., Voskamp-Visser, I., van Hooft, P.A.V., Mars-Groenendijk, R.H., de Visser, P.C., and Noort, D. 2006. Evaluation of the antibacterial spectrum of drosocin analogues. Chem. Biol. Drug Des. 68, 148-153.
11. Boman, H.G. 2000. Innate immunity and the normal microflora. Immunol. Rev. 173, 5-16.
12. Brook, I., Elliott, T.B., Pryor II, H.I., Sautter, T.E., Gnade, B.T., Thakar, J.H., and Knudson, G.B. 2001. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int. J. Antimicrob. Agents 18, 559-562.
13. Brumfitt, W., Salton, M.R.J., and Hamilton-Miller, J.M.T. 2002. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 50, 731-734.
14. Casadevall, A. 2002. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8, 833-841.
15. Casadevall, A. and Pirofski, L.-A. 2005. The potential of antibody-mediated immunity in the defence against biological weapons. Exp. Opinion Biol. Ther. 5, 1359-1372.
16. Chan, D.I., Prenner, E.J., and Vogel, H.J. 2006. Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochim. Biophys. Acta 1758, 1184-1202.
17. Che, Q., Zhou, Y., Yang, H., Li, J., Xu, X., and Lai, R. 2008. A novel antimicrobial peptide from amphibian skin secretions of Odorrana grahami. Peptides 29, 529-535.
18. Chen, Y., Vasil, A., Rehaume, L., Mant, C.T., Burns, J.L., Vasil, M.L., Hancock, R.E.W., and Hodges, R.S. 2006. Comparison of biophysical and biologic properties of α-helical enantiomer antimicrobial peptides. Chem. Biol. Drug Des. 67, 162-173.
19. Chen, Y., Guarnieri, M.T., Vasil, A.I., Vasil, M.L., Mant, C.T., and Hodges, R.S. 2007. Role of peptide hydrophobicity in the mechanism of action of α-helical antimicrobial peptides. Antimicrob. Agents Chemother. 51, 1398-1406.
20. Čipáková, I., Gašperik, J., and Hostinová, E. 2006. Expression and purification of human antimicrobial peptide, dermcidin, in Escherichia coli. Prot. Express. Purific. 45, 269-274.
21. Conlon, J.M., Al-Ghaferi, N., Abraham, B., Sonnevend, A., King, J.D., and Nielsen, P.F. 2006. Purification and properties of laticeptin, an antimicrobial peptide from skin secretions of the South American frog Leptodactylus laticeps. Prot. Pept. Lett. 13, 411-415.
22. Cuesta, A., Meseguer, J., and Esteban, M.A. 2008. The antimicrobial peptide hepcidin exerts an important role in the innate immunity against bacteria in the bony fish gilthead seabream. Mol. Immunol. 45, 2333-2342.
23. da Silva, A.P., Unks, D., Lyu, S.C., Ma, J., Zbozien-Pacamaj, R., Chen, X., Krensky, A.M., and Clayberger, C. 2008. In vitro and in vivo antimicrobial activity of granulysin-derived peptides against Vibrio cholerae. J. Antimicrob. Chemother. 61, 1103-1109.
24. Dennison, S.R., Howe, J., Morton, L.H., Brandenburg, G.K., Harris, F., and Phoenix, D.A. 2006. Interactions of an anionic antimicrobial peptide with Staphylococcus aureus membranes. Biochem. Biophys. Res. Commun. 347, 1006-1010.
25. De Smet, K., and Contreras, R. 2005. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 27, 1137-1147.
26. Dire, D.J. 2004. CBRNE - Biological Warfare Agents. eMedicine. http://www.emedicine.com/emerg/topic853.htm
27. Dürr, H.N., Sudheendra, U.S., and Ramamoorthy, A. 2006. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta 1758, 1408-1425.
28. Eckert, R., He, J., Yarbrough, D.K., Qi, F., Anderson, M.H., and Shi, W. 2006a. Targeted killing of Streptococcus mutans by a pheromone-guided "smart antimicrobial peptide". Antimicrob. Agents Chemother. 50, 3651-3657.
29. Eckert, R., Brady, K.M., Greenberg, P., Qi, F., Yarbrough, D.K., He, J., McHardy, I., Anderson, M.H., and Shi, W. 2006b. Enhancement of antimicrobial activity against Pseudomonas aeruginosa by coadministration of G10KHc and tobramycin. Antimicrob. Agents Chemother. 50, 3833-3838.
30. Eckert, R, F., Qi, D.K., Yarbrough, He, J., Anderson, M.H., and Shi, W. 2006c. Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp. Antimicrob Agents Chemother. 50, 1480-1488.
31. Falciani, C., Lozzi, L., Pini, A., Corti, F., Fabbrini, M., Bernini, A., Lelli, B., Niccolai, N., and Bracci, L. 2007. Molecular basis of branched peptides resistance to enzyme proteolysis. Chem. Biol. Drug Des. 69, 216-221.
32. Fedders, H., and Leippe, M. 2008. A reverse search for antimicrobial peptides in Ciona intestinalis: Identification of a gene family expressed in hemocytes and evaluation of activity. Dev. Comp. Immunol. 32, 286-298.
33. Fernandes, J.M.O., Saint, N., Kemp, G.D., and Smith, V.J. 2003. OncorhyncinIII: A potent antimicrobial peptide derived from the non-histone chromosal protein H6 of rainbow trout, Oncorhynchus mykiss. Biochem. J. 373, 621-628.
34. Gelhaus, C., Jacobs, T., Andrä, J., and Leippe, M. 2008. The antimicrobial peptide NK-2, the core region of mammalian NK-lysin, kills intraerythrocyte Plasmodium falciparum. Antimicrob. Agents Chemother. 52, 1713-1720.
35. Gregory, S.M., Cavenaugh, A., Joirnigan, V., Pokorny, A., and Almeida, P.F.F. 2008. A quantitative model for the all-or-none permeabilization of phospholipid vesicles by the antimicrobial peptide cecropin A. Biophys. J. 94, 1667-1680.
36. Gordon, Y.J., Romanowski, E.G., and McDermott, A.M. 2005. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 30, 505-515.
37. Gros, E., Deshayes, S., Morris, M.C., Aldrian-Herrada, G., Depollier, J., Heitz, F., and Divita, G. 2006. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim. Biophys. Acta 1758, 384-393.
38. Hansen, J.N. 2005. Compositions and methods of inhibiting bacterial spore germination. Patent Application Number: 6953683.
39. Hartley, P.G., Alderton, M.R., Dawson, R.M., and Wells, D. 2007. Ricin antitoxins based on lytotropic mesophases containing galactose amphiphiles. Bioconj. Chem. 18, 152-159.
40. Hong, I.-P., Lee, S.-J., Kim, Y.-S., and Choi, S.-G. 2007. Recombinant expression of human cathelicidin (hCAP18/LL-37) in Pichia pastoris. Biotechnol. Lett. 29, 73-78.
41. Hoskin, D.W., and Ramamoorthy, A. 2008. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys Acta 1778, 357-375.
42. Jenssen H., Hamill, P., and Hancock, R.E.W. 2006. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19, 491-511.
43. Jin, F., Xu, X., Wang, L., Zhang, W., and Gu, D. 2006. Expression of recombinant hybrid peptide cecropin A (1-8) - magainin 2 (1-12) in Pichia pistoris: Purification and characterization. Prot. Express. Purif. 50, 147-156.
44. Kim, C. and Kaufmann, S.H.E. 2006. Defensin: a multifunctional molecule lives up to its versatile name. Trends Microbiol. 14, 428-431.
45. Kim, C., Gajendran, N., Mittrücker, H.-W., Weiwad, M., Song, Y.-H., Hurwitz, R., Wilmanns, M., Fischer, G., and Kaufmann, S.H.E. 2005. Human α-defensins neutralize anthrax lethal toxin and protect against its fatal consequences. Proc. Natl. Acad. Sci. USA. 102, 4830-4835.
46. Konno, K., Hisada, M., Naoki, H., Itagaki, Y., Fontana, R., Rangel, M., Oliveira, J.S., Perez dos Santos Cabrera, M., Neto, J.R., Hide, I., Nakata, Y., Yasuhara, T., and Nakajima, T. 2006. Eumenitin, a novel antimicrobial peptide from the venom of the solitary eumenine wasp Eumenes rubronotatus. Peptides 27, 2624-2631.
47. Lee, D.L., and Hodges, R.S 2003. Structure-activity relationships of de novo designed cyclic antimicrobial peptides based on gramicidin S. Biopolymers (Pept. Sci.) 71, 28-48.
48. Lee, J.-U., Kang, D.-I., Zhu, W.L., Shin, S.Y., Hahm, K.-S., and Kim, Y. 2007. Solution structures and biological functions of the antimicrobial peptide, arenicin-1, and its linear derivative. Biopolymers (Pept. Sci.) 88, 208-216.
49. Li, M., Lai, Y., Villaruz, A.E., Cha, D.J., Sturdevant, D.E., and Otto, M. 2007. Gram-positive three-component antimicrobial peptide-sensing system. Proc. Natl. Acad. Sci. USA. 104, 9469-9474.
50. Loose, C., Jensen, K., Rigoutsos, I., and Stephanopoulos, G. 2006. A linguistic model for the rational design of antimicrobial peptides. Nature 443, 867-869.
51. Lopez-Garcia, B., Ubhayasekera, W., Gallo, R.L., and Marcos, J.F. 2007. Parallel evaluation of antimicrobial peptides derived from the synthetic PAF26 and the human LL37. Biochem. Biophy. Res. Commun. 356, 107-113.
52. Mabry, R., Rani, M., Geiger, R., Hubbard, G.B., Carrion, R., Brasky, K., Patterson, J.L., Georgiou, G., and Iverson, B.L. 2005. Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect. Immun. 73, 8362-8368.
53. Malmsten, M., Davoudi, M., Walse, B., Rydeng̊ard, V., Pasupuletti, M., Mörgelin, M., and Schmidtchen, A. 2007. Antimicrobial peptides derived from growth factors. Growth Factors 25, 60-70.
54. Marr, A.K., Gooderham, W.J., and Hancock, R.E.W. 2006. Antibacterial peptides for therapeutic use: obstacles and realistic outlook. Curr. Opinion Pharmacol. 6, 468-472.
55. Maynard, J.A., Maassen, C.B.M., Leppla, S.H., Brasky, K., Patterson, J.L., Iverson, B.L., and Georgiou, G. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nature Biotechnol. 20, 597-601.
56. Misir, A.J. 2002. The Fourth Horseman's Armored Cavalry: The Technology of Bioterrorism in the Early 21st Century. University of Toronto Medical Journal 79, 133-135.
57. Montville, T.J., De Siano, T., Nock, A., Padhi, S., and Wade, D. 2006. Inhibition of Bacillus anthracis and potential surrogate bacilli growth from spore inocula by nisin and other antimicrobial peptides. J. Food Prot. 69, 2529-2533.
58. Morris, M.C., Depollier, J., Mery, J., Heitz, F., and Divita, G. 2001. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nature Biotechnol. 19, 1173-1176.
59. Nagao, J.-i., Asaduzzaman, S.M., Aso, Y., Okuda, K.-i., Nakayama, J., and Sonomoto, K. 2006. Lantiobiotics: Insight and foresight for new paradigm. J. Biosci. Bioeng. 102, 139-149.
60. Nageoka I., Huwahara-Arai, K., Tamura, H., Hiramatsu, K., and Hirata, M. 2005. Augmentation of the bactericidal activities of human cathelicidin CAP18/LL-37-derived antimicrobial peptides by amino acid substitutions. Inflamm. Res. 54, 66-73.
61. Nan, Y.H., Jeon, Y.J., Park, I.-S., and Shin, S.Y. 2008. Antimicrobial peptide P18 inhibits inflammatory responses by LPS- but not by IFN-̃-stimulated macrophages. Biotechnol. Lett. 30, In press.
62. Niu, M., Li, X., Wei, J., Cao, R., Zhou, B., and Chen, P. 2008. The molecular design of a recombinant antimicrobial peptide CP and its in vitro activity. Prot. Express. Purif. 57, 95-100.
63. Nizet, V. 2006. Antimicrobial peptide resistance mechanisms of human bacterial pathogens. Curr. Issues Molec. Biol. 8, 11-26.
64. Ovchinnikova, T.V., Balandin, S.V., Aleshina, G.M., Tagaev, A.A., Leonova, Y.F., Krasnodembsky, E.D., Men'shenin, A.V., and Kokryakov, V.N. 2006. Aurelin, a novel antimicrobial peptide from jellyfish Aurelia aurita with structural features of defensins and channel-blocking toxins. Biochem. Biophys. Res. Commun. 348, 514-523.
65. Pál, T., Sonnevend, Á., Galadari, S., and Conlon, J.M., 2005. Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide pseudin-2. Reg. Pept. 129, 85-91.
66. Park, H.K., Lim, H.-T., Chae, B.J., Hahm, K.-S., and Park, Y. 2008. Influence of the N- and C-terminal regions of Leu-Lys rich antimicrobial peptide on antimicrobial activity. Prot. Pept. Lett. 15, 188-192.
67. Park, Y., Park, S.-C., Park, H.-K., Shin, S.Y., Kim, Y., and Hahm, K.-S. 2007. Structure-activity relationship of HP (2-20) analog peptide: Enhanced antimicrobial activity by N-terminal random coil region deletion. Biopolymers (Pept. Sci.) 88, 199-207.
68. Pini, A., Runci, Y., Falciani, C., Lelli, B., Brunetti, J., Pileri, S., Fabbrini, M., Lozzi, L., Ricci, C., Bernini, A., Tonello, F., Dal Molin, F., Neri, P., Niccolai, N., and Bracci, L. 2006. Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo. Biochem. J. 395, 157-163.
69. Pini, A., Giuliani, A., Falciani, C., Fabbrini, M., Pileri, S., Lelli, B., and Bracci, L. 2007. Characterization of the branched antimicrobial peptide M6 by analysing its mechanism of action and in vivo toxicity. J. Pept. Sc. 13, 393-399.
70. Pirofski, L-A., and Casadevall, A. 1998. The use of licensed vaccines for active immunization of the immunocompromised host. Clin. Microbiol. Rev. 11, 1-26.
71. Pistolesi, S., Pogni, R., and Feix, J.B. 2007. Membrane insertion and bilayer perturbation by antimicrobial peptide CM15. Biophys. J. 93, 1651-1660.
72. Polyzos, A., Alderton, M.R., Dawson, R.M., and Hartley, P.G. 2007. Biofunctionalized surfactant mesophases as polyvalent inhibitors of cholera toxin. Bioconj. Chem. 18, 1442-1449.
73. Sang Y., Ortega, M.T., Rune, K., Xiau, W., Zhang, G., Soulages, J.L., Lushington, G.H., Fang, J., Williams, T.D., Blecha, F., and Melgarejo, T. 2007. Canine cathelicidin (K9CATH): Gene cloning, expression, and biochemical activity of a novel pro-myeloid antimicrobial peptide. Dev. Comp. Immunol. 31, 1278-1296.
74. Schmitt, P., Mercado, L., Diaz, M., Guzmán, F., Arenas, G., and Marshall, S.H. 2008. Characterization and functional recovery of a novel antimicrobial peptide (CECdir-CECret) from inclusion bodies after expression in Escherichia coli. Peptides 29, 512-519.
75. Seebah, S., Suresh, A., Zhuo, S., Choong, Y.H., Chua, H., Chuon, D., Beuerman, R., and Verma, C. 2007. Defensins knowledgebase: a manually curated database and information source focused on the defensins family of antimicrobial peptides. Nucleic Acids Res. 35, D265-D268.
76. Shai Y., Makovitzky, A., and Avrahami, D. 2006. Host defense peptides and lipopeptides: Modes of action and potential candidates for the treatment of bacterial and fungal infections. Curr. Protein Pept. Sci. 7, 479-486.
77. Shankaramma, S.C., Athanassiou, Z., Zerbe, O., Moehle, K., Mouton, C., Bernardini, F., Vrijbloed, D., and Robinson, J.A. 2006. Macrocyclic hairpin mimetics of the cationic antimicrobial peptide protegrin I: A new family of broad-spectrum antibiotics. Chem. Bio. Chem. 3, 1126-1133.
78. Sigurardotir, T., Andersson, P., Davoudi, M., Malmsten, M., Schmidtchen, A., and Bodelsson, M. 2006. In silico identification and biological evaluation of antimicrobial peptides based on human cathelicidin LL-37. Antimicrob. Agents Chemother. 50, 2983-2939.
79. Steffen, H., Rieg, S., Wiedemann, I., Kalbacher, H., Deeg, M., Sahl, H.-G., Peschel, A., Götz, F., Garbe, C., and Schittek, B. 2006. Naturally processed dermcidin-derived peptides do not permeabilize bacterial membranes and kill microorganisms irrespective of their charge. Antimicrob. Agents Chemother. 50, 2608-2620.
80. Stepanov, A.V., Marinin, L.I., Pomerantsev, A.P., and Staritsin, N.A. 1996. Development of novel vaccines against anthrax in man. J. Biotechnol. 44, 155-160.
81. Thwaite, J.E., Hobbs, S., Titball, R.W., and Atkins, T.P. 2006. Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence. Antimicrob. Agents Chemother. 50, 2316-2322.
82. Wagstaff, K.M., and Jans, D.A. 2006. Protein transduction: Cell penetrating peptides and their therapeutic applications. Curr. Med. Chem. 13, 1371-1387.
83. Wang, W., Mulakala, C., Ward, S.C., Jung, G., Luong, H., Pham, D., Waring, A.J., Kaznessis, Y., Lu, W., Bradley, K.A., and Lehrer, R.I. 2006. Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin. J. Biol. Chem. 281, 37255-32764.
84. Xiao, Y., Dai, H., Bommineni, Y.R., Soulages, J.L., Gong, Y.-X., Prakash, O., and Zhang, G. 2006. Structure-activity relationships of fowlicidin-1, a cathelicidin antimicrobial peptide in chickens. FEBS J. 273, 2581-2593.
85. Xu, F., Meng, K., Wang, Y.-R., Luo, H.-Y., Yang, P.-L., Wu, N.-F., Fan, Y.-L., and Yao, B. 2008. Eukaryotic expression and antimicrobial spectrum determination of the peptide tachyplesin II. Prot. Express. Purific. 58, 175-183.
86. Yamada, Y., Miura, Y., Sakaki, A., Yoshida, T., and Kobayashi, K. 2006. Design of multifunctional peptides expressing both antimicrobial activity and shiga toxin neutralization activity. Bioorg. Med. Chem. 14, 77-82.
87. Yasin, B., Wang, W., Pang, M., Cheshenko, N., Hong, T., Waring, A.J., Herold, B.C., Wagar, E.A., and Lehrer, R.T. 2004. θ Defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J. Virol. 78, 5147-5156.
88. Yeaman, M.R., and Yount, N.Y. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55, 27-55.
89. Zaiou, M. 2007. Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J. Mol. Med. 85, 317-329.
90. Zelezetsky, I., Pag, U., Antcheva, N., Sahl, H.-G., and Tossi, A. 2005. Identification and optimization of an antimicrobial peptide from the ant venom toxin pilosulin. Arch. Biochem. Biophys. 434, 358-364.
91. Zhang, L., and Falla, T.J. 2006. Antimicrobial peptides: therapeutic potential. Exp. Opinion Pharmacother. 7, 653-663.
92. Zhao, H., Lee, W.-H., Shen, J.-H., Li, H., Zhang, Y. 2008. Identification of novel semenogelin I-derived antimicrobial peptide from liquefied human seminal plasma. Peptides 29, 505-511.
93. Zhou, J., McClean, S., Thompson, A., Zhang, Y., Shaw, C., Rao, P., and Bjourso, A.J. 2006. Purification and characterization of novel antimicrobial peptides from the skin secretion of Hylarana guentheri. Peptides 27, 3077-3084.
94. Zhou, Q.-F., Luo, X.-G., Ye, L., and Xi, T. 2007. High-level production of a novel antimicrobial peptide perinerin in Escherichia coli by fusion expression. Curr. Microbiol. 54, 366-370.
95. Zhu, W.L., Lan, H., Park, I.-S., Kim, J.I., Jin, H.Z., Hahm, K.-S., and Shin, S.Y. 2006a. Design and mechanism of action of a novel bacteria-selective antimicrobial peptide from the cell-penetrating peptide Pep-1. Biochem. Biophys. Res. Commun. 349, 769-774.
96. Zhu, W.L., Lan, H., Park, Y., Yang, S.-T., Kim, J.I., Park, I.-S., You, H.J., Lee, J.S., Park, Y.S., Kim, Y., Hahm, K.-S.and Shin, S.Y. 2006b. Effects of Pro → peptoid residue substitution on cell selectivity and mechanism of antibacterial action of tritrpticin-amide antimicrobial peptide. Biochemistry 45, 13007-13017.
97. Zhu, W.L., Hahm , K.-S., and Shin, S.Y. 2007. Cathelicidin-derived Trp/Pro-rich antimicrobial peptides with lysine peptoid residue (Nlys): therapeutic index and plausible mode of action. J. Peptide Sci. 13, 529-535.